Royal Bank of Canada
MDGL icon

Royal Bank of Canada’s Madrigal Pharmaceuticals MDGL Stock Holding History

Royal Bank of Canada’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.56M Buy
12,526
+2,303
+23% +$1.1M ﹤0.01% 2217
2025
Q4 		$5.95M Sell
10,223
-9,950
-49% -$5.08M ﹤0.01% 2289
2025
Q3 		$9.25M Buy
20,173
+10,570
+110% +$3.94M ﹤0.01% 2204
2025
Q2 		$2.91M Buy
9,603
+784
+9% +$234K ﹤0.01% 3012
2025
Q1 		$2.92M Sell
8,819
-2,571
-23% -$845K ﹤0.01% 2665
2024
Q4 		$3.52M Buy
11,390
+1,742
+18% +$490K ﹤0.01% 2603
2024
Q3 		$2.05M Buy
9,648
+1,273
+15% +$326K ﹤0.01% 2985
2024
Q2 		$2.35M Buy
8,375
+5,864
+234% +$1.4M ﹤0.01% 2793
2024
Q1 		$671K Sell
2,511
-4,204
-63% -$991K ﹤0.01% 3767
2023
Q4 		$1.55M Buy
6,715
+4,493
+202% +$786K ﹤0.01% 3279
2023
Q3 		$324K Sell
2,222
-9,166
-80% -$1.73M ﹤0.01% 4382
2023
Q2 		$2.63M Sell
11,388
-1,583
-12% -$429K ﹤0.01% 2621
2023
Q1 		$3.14M Sell
12,971
-179
-1% -$48.8K ﹤0.01% 2449
2022
Q4 		$3.82M Buy
13,150
+2,570
+24% +$251K ﹤0.01% 2345
2022
Q3 		$688K Buy
10,580
+83
+0.8% +$5.77K ﹤0.01% 3755
2022
Q2 		$751K Sell
10,497
-652
-6% -$47.9K ﹤0.01% 3735
2022
Q1 		$1.09M Sell
11,149
-1,961
-15% -$165K ﹤0.01% 3573
2021
Q4 		$1.11M Buy
13,110
+5,237
+67% +$430K ﹤0.01% 3698
2021
Q3 		$629K Buy
7,873
+174
+2% +$15K ﹤0.01% 4158
2021
Q2 		$751K Buy
7,699
+7,332
+1,998% +$868K ﹤0.01% 3916
2021
Q1 		$43K Buy
367
+223
+155% +$26K ﹤0.01% 5986
2020
Q4 		$16K Buy
144
+18
+14% +$2.2K ﹤0.01% 6164
2020
Q3 		$15K Buy
126
+65
+107% +$7.06K ﹤0.01% 5794
2020
Q2 		$7K Sell
61
-29
-32% -$2.85K ﹤0.01% 5951
2020
Q1 		$6K Sell
90
-265
-75% -$22.1K ﹤0.01% 5986
2019
Q4 		$33K Buy
355
+263
+286% +$25.5K ﹤0.01% 5642
2019
Q3 		$8K Hold
92
– – ﹤0.01% 5851
2019
Q2 		$10K Sell
92
-30
-25% -$3.21K ﹤0.01% 6026
2019
Q1 		$15K Sell
122
-11
-8% -$1.37K ﹤0.01% 5790
2018
Q4 		$15K Sell
133
-258
-66% -$39.9K ﹤0.01% 5705
2018
Q3 		$83K Sell
391
-8,900
-96% -$2.23M ﹤0.01% 4960
2018
Q2 		$2.6M Sell
9,291
-13
-0.1% -$2.28K ﹤0.01% 2527
2018
Q1 		$1.09M Sell
9,304
-97
-1% -$12K ﹤0.01% 3113
2017
Q4 		$863K Sell
9,401
-152
-2% -$8.68K ﹤0.01% 3337
2017
Q3 		$430K Buy
9,553
+9,366
+5,009% +$175K ﹤0.01% 3921
2017
Q2 		$3K Buy
187
+142
+316% +$2.22K ﹤0.01% 6193
2017
Q1 		$1K Buy
45
+3
+7% +$47 ﹤0.01% 6517
2016
Q4 		$1K Hold
42
– – ﹤0.01% 6557
2016
Q3 		$1K Sell
42
-72
-63% -$698 ﹤0.01% 6288
2016
Q2 		$1K Buy
114
+57
+100% +$684 ﹤0.01% 6247
2016
Q1 		$0 Sell
57
-14
-20% -$117 ﹤0.01% 6542
2015
Q4 		$1K Sell
71
-298
-81% -$8.18K ﹤0.01% 6481
2015
Q3 		$22K Sell
369
-224
-38% -$16.2K ﹤0.01% 5526
2015
Q2 		$46K Sell
593
-796
-57% -$66.8K ﹤0.01% 5261
2015
Q1 		$94K Buy
1,389
+151
+12% +$12.9K ﹤0.01% 4651
2014
Q4 		$115K Sell
1,238
-881
-42% -$91.1K ﹤0.01% 4659
2014
Q3 		$223K Buy
2,119
+1,833
+641% +$255K ﹤0.01% 4121
2014
Q2 		$41K Sell
286
-57
-17% -$8.33K ﹤0.01% 4943
2014
Q1 		$52K Buy
+343
New +$67.6K ﹤0.01% 4848
2013
Q4 		– Sell
-89
Closed -$20K – 6048
2013
Q3 		$20K Buy
89
+3
+3% +$638 ﹤0.01% 5177
2013
Q2 		$15K Buy
+86
New +$22.4K ﹤0.01% 5133

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royal Bank of Canada's MDGL Position: Q1 2026 in Review

Royal Bank of Canada increased its Madrigal Pharmaceuticals (MDGL) stake by 23% in Q1 2026, buying an estimated $1.1M and bringing the position to 12,526 shares worth $6.56M. The position accounts for ﹤0.01% of the portfolio, ranked #2217.

Royal Bank of Canada first reported a position in MDGL in Q2 2013 and has held it in 51 quarters since. The position peaked at $9.25M in Q3 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Royal Bank of Canada held 12,526 shares of Madrigal Pharmaceuticals worth $6.56M as of Q1 2026.
  • Royal Bank of Canada bought 2,303 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $1.1M.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #2217 holding.
  • Royal Bank of Canada first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
  • Royal Bank of Canada's Madrigal Pharmaceuticals position peaked at $9.25M in Q3 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.